Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages 1045-1054

  Woll, Penella J ^a   Reichardt, Peter ^b,c   Le Cesne, Axel ^d   Bonvalot, Sylvie ^d   Azzarelli, Alberto ^e   Hoekstra, Harald J ^f   Leahy, Michael ^g   Van Coevorden, Frits ^h   Verweij, Jaap ⁱ   Hogendoorn, Pancras C W ^j   Ouali, Monia ^k   Marreaud, Sandrine ^k   Bramwell, Vivien H C ^l   Hohenberger, Peter ^b,m  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Section of Pathology   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k EORTC DATA CENTER   (Belgium)

^l Queen's Cancer Research Institute   (Canada)

^m UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HEALTH STATUS; HEART DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; INFECTION; LEIOMYOSARCOMA; LEUKOCYTE COUNT; LIPOSARCOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROSCOPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT PLANNING; TUMOR VOLUME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SARCOMA;

EID: 84866901248     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70346-7     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E Cancer statistics 2010. CA Cancer J Clin 2010, 60:277-300.
2. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679-1689.
3. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994, 12:1137-1149.
4. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993, 11:15-21.
5. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984, 33:37-42.
6. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. Proc Am Soc Clin Oncol 2007, 25(suppl):10008.
7. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13:1537-1545.
8. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2676-2684.
9. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997, 350:1647-1654. Sarcoma Meta-Analysis Collaboration.
10. Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma 2000, 4:151-160.
11. Fakhrai N, Ebm C, Kostler WJ, et al. Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. Wien Klin Wochenschr 2010, 122:614-619.
12. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative trial. J Clin Oncol 2001, 19:1238-1247.
13. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003, 65(suppl 2):80-84.
14. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002, 25:468-473.
15. Mantel N, Haenszel W Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
16. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta analyses. Br Med J 2003, 327:557-560.
18. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
19. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113:573-581.
20. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001, 37:1096-1103.
21. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010, 11:561-570.